
The World Health Organization (WHO) is likely to decide on permitting Emergency Use Listing (EUL) to Bharat Biotech International Ltd’s (BBIL) Covid vaccine Covaxin in four to six weeks, WHO Chief Scientist Soumya Swaminathan has said.
BBIL that produces Covid-19 Covaxin vaccine has reportedly submitted almost complete documentation required for obtaining EUL. Upon granted with EUL, it will enable the domestically-developed Covid vaccine Covaxin to be accepted as well as used by other nations.

“It is mandatory to supply a complete dossier listing safety, efficacy and manufacturing conditions of the vaccine to the WHO. I understand that Bharat Biotech is in this process and I think a decision on their case is likely in the next four to six weeks,” Swaminathan has been quoted as saying by The Hindu.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!